Creative Planning’s bioAffinity Technologies BIAF Stock Holding History

Creative Planning’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-403	Closed	-$3.47K	–	3923
2025 Q2	$3.47K	Hold	403	–	–	﹤0.01%	3653
2025 Q1	$3.15K	Hold	403	–	–	﹤0.01%	3448
2024 Q4	$11K	Hold	403	–	–	﹤0.01%	3380
2024 Q3	$25.2K	Sell	403 -17	-4%	-$1.02K	﹤0.01%	3139
2024 Q2	$27.2K	Buy	420 +17	+4%	+$1.18K	﹤0.01%	2970
2024 Q1	$24.4K	Hold	403	–	–	﹤0.01%	2826
2023 Q4	$17.8K	Hold	403	–	–	﹤0.01%	2702
2023 Q3	$14.1K	Hold	403	–	–	﹤0.01%	2618
2023 Q2	$22.1K	Hold	403	–	–	﹤0.01%	2501
2023 Q1	$22.9K	Hold	403	–	–	﹤0.01%	2401
2022 Q4	$19.4K	Sell	403 -582	-59%	-$44.2K	﹤0.01%	2316
2022 Q3	$86K	Buy	+985	New	+$124K	﹤0.01%	2052

Other funds holding BIAF

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LFG

Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return

Creative Planning's BIAF Position: Q3 2025 in Review

Creative Planning sold out of bioAffinity Technologies (BIAF) in Q3 2025, closing a stake of 403 shares — an estimated $3.47K sold.

Creative Planning first reported a position in BIAF in Q3 2022 and held it in 12 quarters. The position peaked at $86K in Q3 2022. 12 funds tracked by Wall St. Rank hold BIAF as of Q3 2025.

Creative Planning reported no remaining bioAffinity Technologies position as of Q3 2025 after selling out during the quarter.
Creative Planning sold 403 bioAffinity Technologies shares in Q3 2025, an estimated $3.47K.
Creative Planning first reported a position in bioAffinity Technologies in Q3 2022 and held it in 12 quarters.
Creative Planning's bioAffinity Technologies position peaked at $86K in Q3 2022.
12 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2025.

Based on Creative Planning's 13F filing for Q3 2025, filed 14 Nov 2025.